Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer

SIMPLE SUMMARY: Current standard clinical risk-stratification systems do not sufficiently reflect the disease heterogeneity for prostate cancer. Intermediate risk prostate cancer represents a highly heterogeneous risk group with different treatment options available such as surgery, radiation therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Belkacemi, Yazid, Debbi, Kamel, Coraggio, Gabriele, Bendavid, Jérome, Nourieh, Maya, To, Nhu Hanh, Cherif, Mohamed Aziz, Saldana, Carolina, Ingels, Alexandre, De La Taille, Alexandre, Loganadane, Gokoulakrichenane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913491/
https://www.ncbi.nlm.nih.gov/pubmed/36765902
http://dx.doi.org/10.3390/cancers15030945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913491/
https://www.ncbi.nlm.nih.gov/pubmed/36765902
http://dx.doi.org/10.3390/cancers15030945

Ejemplares similares